Aura Biosciences, Inc. (AURA): Cash & Equivalents
$59.52M
As of 2025-12-31
$67.84M
As of 2026-06-30
-21.2%
3-year compound annual growth
+27.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.52M | +87.8% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $31.69M | -22.8% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $41.06M | -66.2% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $121.58M | -18.4% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $149.06M | +757.0% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $17.39M | n/a | 2022-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $59.52M | +87.8% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $10.50M | +18.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $82.98M | -49.4% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $12.36M | -24.1% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $178.80M | +83.4% |
| Compugen Ltd (CGEN) | 2025-12-31 | $90.60M | +397.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $110.82M | +29.0% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
Compare AURA, SABS, STRO, CABA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗